News | August 24, 2010

100 Percent Neointimal Strut Coverage Reported With New Stent

August 24, 2010 – Optical coherence tomography (OCT) evaluation of a patient with anterior ST-elevation myocardial infarction (STEMI) who received two OrbusNeich Genous Bio-engineered R stents showed 100 percent coverage of the stent struts and complete neointimal coverage 26 days post-implantation.

Stephen Wai-Luen Lee, MBBS, of the Queen Mary Hospital in Hong Kong presented the findings in a presentation, "Genous Combo – The Latest of Novel Devices in the Evolution of the Coronary Intervention," as part of a symposium at the Annual Meeting of the Japanese Association of Cardiovascular Intervention and Therapeutics.

Following a diagnosis of acute thrombotic occlusion of the proximal left anterior descending artery (LAD), with critical lesions identified in the proximal and mid LAD and a chronic total occlusion (CTO) of the proximal right coronary artery (RCA), the patient, a 62-year-old male, received two 2.5 mm-diameter Genous Bio-engineered R stents. The proximal stent was 23 mm in length, and the distal stent was 13 mm in length. At 26 days post-implantation, physicians conducted an OCT assessment when a staged procedure was performed to the CTO on the RCA with implantation of an additional 2.5 mm-diameter by 23 mm-length Genous Bio-engineered R stent.

"This is the first documentation of complete endothelialization after 26 days of Genous stent implantation, showing the pro-healing effect in vivo,” Lee said.

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

OrbusNeich's Genous Bio-engineered R stent has been commercially available in more than 60 countries since 2005. The Genous stent has been proven as a safe, effective alternative to drug-eluting stents and is supported by data from more than 5,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

For more information: www.OrbusNeich.com

Related Content

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent. #TCT2018

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent.

News | Stents | October 04, 2018
October 4, 2018 – Investigators unveiled clinical data from the independent BIONYX and SORT OUT IX all-comers trials
FDA Approves Biotronik's PK Papyrus Stent for Coronary Perforations
Technology | Stents | September 27, 2018
September 27, 2018 — Biotronik recently announced U.S.
Videos | Stents | September 11, 2018
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init